Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 11:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 769–792 of 4,234 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Study Product Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Multiple-ascending Doses of IW-3300 in Healthy Subjects

NCT05362695
View directory record Official record
Conditions
Healthy Volunteers
Interventions
IW-3300, Placebo
Drug
Lead sponsor
Ironwood Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Efficacy, Safety and Tolerability of PSD502 (a Topical Anesthetic) in the Treatment Premature Ejaculation

NCT00556478
View directory record Official record
Conditions
Premature Ejaculation
Interventions
PSD502, contains a mixture of lidocaine and prilocaine, Placebo
Drug
Lead sponsor
Plethora Solutions Ltd
Industry
Eligibility
18 Years and older · Male only
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Oct 23, 2026, 11:35 AM EDT
Recruiting Phase 3 Interventional

Propofol and Etomidate Admixtures Comparisons Trial (PEAC Trial)

NCT05358535
View directory record Official record
Conditions
Anesthesia, Propofol Adverse Reaction, Etomidate Adverse Reaction, Anesthesia Complication, Anesthesia; Adverse Effect, Anesthesia; Reaction
Interventions
Admixture of propofol and etomidate at a ratio by volume of 75%/25% (P7E2), Admixture of propofol and etomidate at a ratio by volume of 25%/75% (P2E7)
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Not applicable Interventional Results available

Clinical Study Evaluating the Performance of HEMOBLAST Bellows Compared to FLOSEAL Hemostatic Matrix in Cardiothoracic Operations

NCT03725098
View directory record Official record
Conditions
Cardiothoracic Surgery
Interventions
HEMOBLAST Bellows, FLOSEAL
Device
Lead sponsor
Biom'Up France SAS
Industry
Eligibility
Not listed
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
4
States / cities
Los Angeles, California • Honolulu, Hawaii • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2020 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 2 Interventional Results available

A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263

NCT01128621
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
GSK1292263, GSK1292263 matching placebo, Sitagliptin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Not applicable Interventional

Concurrent Treatment for Substance Dependent Individuals With Post-Traumatic Stress Disorder (PTSD)

NCT01365247
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic, Substance-Related Disorders
Interventions
Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure, Relapse Prevention Treatment, Active Monitoring Control Group
Behavioral
Lead sponsor
The City College of New York
Other
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2015 · Synced Oct 23, 2026, 11:35 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

CPMC Early Undifferentiated Arthritis Registry

NCT02353221
View directory record Official record
Conditions
Early Undifferentiated Arthritis
Interventions
Not listed
Lead sponsor
California Pacific Medical Center Research Institute
Other
Eligibility
18 Years to 95 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Mar 9, 2022 · Synced Oct 23, 2026, 11:35 AM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Longjohn Amgen Study - Effect of Denosumab...

NCT02444585
View directory record Official record
Conditions
Arthroplasty, Replacement, Hip
Interventions
Denosumab
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 75 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

NCT04622293
View directory record Official record
Conditions
Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Interventions
Solriamfetol Oral Tablet [Sunosi], Placebo
Drug
Lead sponsor
Rochester Center for Behavioral Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
1
States / cities
Rochester Hills, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 6, 2025 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Safety and Tolerability Study of 10XB-101 Injection in Adult Subjects With Submental Fat

NCT05154955
View directory record Official record
Conditions
Submental Fat
Interventions
10XB-101 Solution for Injection, 10XB-101 Vehicle Solution for Injection
Drug
Lead sponsor
10xBio, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Encino, California • San Diego, California • Rolling Meadows, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 29, 2025 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of Pre-Meal Whey Protein Microgels Administration on Post-Prandial Glycemic Response.

NCT04639726
View directory record Official record
Conditions
Dietary Supplement
Interventions
Whey Protein Micro Gel, Water without Whey Protein.
Dietary Supplement · Other
Lead sponsor
Société des Produits Nestlé (SPN)
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Oct 15, 2024 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 2 Interventional Results available

Pentoxifylline and Combination Antiretroviral Therapy to Improve Blood Vessel Function in HIV-Infected People

NCT00864916
View directory record Official record
Conditions
HIV, Vascular Diseases, Cardiovascular Diseases, Atherosclerosis, HIV Infections
Interventions
Combination antiretroviral therapy (cART), Pentoxifylline, Placebo
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 12, 2014 · Synced Oct 23, 2026, 11:35 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

ANCHORS Alcohol & Sexual Health Study: UH3 Project

NCT04331704
View directory record Official record
Conditions
Alcohol Use, Unspecified, Substance Use, Sex Behavior
Interventions
PrEP acronym (pre-exposure prophylaxis), Initial Web Survey, Interactive Voice Response (IVR) monitoring, Educational material on alcohol and sexual health behavior, Interactive Voice Response (IVR) assessment with personalized information, Personalized information based on web-based survey responses & standardized information
Drug · Behavioral
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease

NCT00626184
View directory record Official record
Conditions
Celiac Disease
Interventions
4 dose levels of ALV003
Drug
Lead sponsor
Alvine Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2009 · Synced Oct 23, 2026, 11:35 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia

NCT03781115
View directory record Official record
Conditions
Schizophrenia
Interventions
Ziprasidone, Olanzapine, Placebo Comparator
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 2 Interventional

Pirfenidone to Treat Hypertrophic Cardiomyopathy

NCT00011076
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Pirfenidone
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of SST 0225, a Topical Ibuprofen Cream, in the Treatment of Pain Associated With Acute Ankle Sprain

NCT01874626
View directory record Official record
Conditions
Acute Ankle Sprain
Interventions
Placebo, SST-0225 Topical Ibuprofen Cream
Drug
Lead sponsor
Strategic Science & Technologies, LLC
Industry
Eligibility
16 Years and older
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Guilford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 21, 2021 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 2 Interventional Results available

A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

NCT05353985
View directory record Official record
Conditions
Celiac Disease
Interventions
TAK-062, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-Bar, TAK-062 Placebo, Simulated Inadvertent Gluten Exposure (SIGE) Gluten-free Bar
Drug · Dietary Supplement
Lead sponsor
Takeda
Industry
Eligibility
12 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
61
States / cities
Birmingham, Alabama • Litchfield Park, Arizona • Paradise Valley, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2025 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Phase 4 Interventional Results available

Use of Dapagliflozin to Reduce Burden of Atrial Fibrillation in Patients Undergoing Catheter Ablation of Symptomatic Atrial Fibrillation

NCT04792190
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
dapagliflozin, Placebo
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Portland, Maine • Detroit, Michigan • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 4, 2024 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Early Phase 1 Interventional

Continuous Femoral Nerve Block With a Tibial Plateau Fracture

NCT02168959
View directory record Official record
Conditions
Tibial Plateau Fracture
Interventions
bupivacaine
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Mar 14, 2016 · Synced Oct 23, 2026, 11:35 AM EDT
Active, not recruiting Phase 2 Interventional

A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.

NCT07228390
View directory record Official record
Conditions
Hidradenitis Suppurativa
Interventions
Ritlecitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
30
States / cities
Hot Springs, Arkansas • Fountain Valley, California • Northridge, California + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 23, 2026, 11:35 AM EDT
Completed Not applicable Interventional Results available

ILLUMENATE Pivotal Post-Approval Study (PAS)

NCT03421561
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Stellarex 0.035" OTW Drug-coated Angioplasty Balloon, EverCross™ 0.035 PTA Balloon Catheter
Device
Lead sponsor
Spectranetics Corporation
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
39
States / cities
Yuma, Arizona • Fremont, California • Los Angeles, California + 34 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2024 · Synced Oct 23, 2026, 11:35 AM EDT
Recruiting Phase 3 Interventional

Randomized Study in Children and Adolescents With Migraine: Acute Treatment

NCT04649242
View directory record Official record
Conditions
Pediatric Migraine
Interventions
Rimegepant/BHV3000, Matching placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
6 Years to 17 Years
Enrollment
2,100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
169
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tempe, Arizona + 107 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2026 · Synced Oct 23, 2026, 11:35 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

NCT06619990
View directory record Official record
Conditions
Ulcerative Colitis (UC)
Interventions
XmAb942, Placebo
Biological · Drug
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
270 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2030
U.S. locations
30
States / cities
Scottsdale, Arizona • Palo Alto, California • Bradenton, Florida + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 23, 2026, 11:35 AM EDT